Categories
Healthcare

Merck Animal Health supports rabies elimination by 2030 on World Rabies Day

Campaign raises awareness about importance of dog vaccination

MADISON, N.J.–(BUSINESS WIRE)–$MRK #ForThemForUs–In recognition of World Rabies Day on September 28, Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the launch of a global campaign to raise awareness among veterinarians, dog owners and volunteers who are committed to eliminate rabies through ongoing dog vaccination efforts. In partnership with Mission Rabies and Rabies Free Africa, the social media initiative recognizes and celebrates those individuals who are committed to protecting and saving canine as well as human lives, using the hashtag, #ForThemForUs.

Many of us love and rely on our dogs, who in many cases are not only much-loved family members, but also hard-working companions,” said Luke Gamble, BVSc, DVM&S, FRCVS, founder, Mission Rabies. “On this World Rabies Day, we want to recognize the invaluable role dogs play in our lives. When we protect our dogs from rabies, we are also protecting ourselves from this deadly disease. Showcasing those efforts through #ForThemForUs moments is a fitting way to raise awareness about why vaccinating dogs and educating people about preventing rabies matters and saves lives.”

Around the world, there are an estimated 900 million dogsi but the majority (75-85%) are not household petsii. In order to prevent rabies transmission in rabies-endemic areas, at least 70% of the dogs there need to be protected through annual mass-vaccinationiii. For over 20 years, Merck Animal Health, through the Afya Program, has been dedicated to rabies prevention and has donated over three million doses of rabies vaccine to help meet the World Health Organization (WHO) “Zero by 2030” goal.

Each year, an estimated 59,000 people die from rabies, with over 99% of cases contracted from a dog bite. Additionally, 40% of those deaths occur in children 15 years and under. This is in part because of low rates of canine vaccination in rabies endemic areas and a lack of awareness about the disease.

With Merck Animal Health, we have made significant progress on the research needed to design cost-effective and efficient vaccination programs that reduce rates of rabies in both dogs and humans,” notes Felix Lankester, DVM, Ph.D., director, Rabies Free Africa, Paul G. Allen School for Global Animal Health, Washington State University. “From scientific research to actual vaccination programs, we are refining the tools we need to prevent rabies. While doing so, we must continue to work together with local governments and healthcare organizations supporting local communities as they continue rabies prevention where it is most needed. This will help us achieve our 2030 rabies elimination goal.”

Collaboration must continue among human, animal and environmental health organizations to advance sustainable rabies prevention efforts, including annual mass-vaccination. Through this One Health approach, local, regional, national and global animal health advocates all have a critical role in addressing this public health threat and must work together to keep both dogs and humans healthy.

Experiencing first-hand the important work of our partners, veterinarians and volunteers was the inspiration behind our campaign, #ForThemForUs,” said Ingrid Deuzeman, global marketing director, Companion Animal Vaccines, Merck Animal Health. “We wanted to recognize the global community for their role in eliminating rabies – from the local veterinarian who vaccinates dogs in a veterinary clinic to the door-to-door efforts of volunteers and the Mission Rabies and Rabies Free Africa teams across the African continent and beyond to vaccinate owned and stray dogs. We hope that by everyone sharing their #ForThemForUs moments with the world, these outstanding individuals and not-for-profit organizations will gain even more awareness and support to expand rabies prevention and elimination efforts.”

For example, as a commitment to rabies vaccination in Goa, India, there have been no recorded human rabies deaths for two years. “During the COVID-19 pandemic, the Mission Rabies local team remained essential to ensure rabies did not re-emerge in the area. Throughout this period, our team was on-call to respond to any reported rabid dogs. After several positive cases were confirmed, they also quickly launched an emergency rabies vaccination drive to prevent spread,” said Gamble.

Veterinarians, dog owners and volunteers are invited to share photos and videos of their inspirational work in keeping dogs rabies-free, using the hashtag, #ForThemForUs.

About Mission Rabies

Mission Rabies was initially founded as an initiative by Worldwide Veterinary Service (WVS), a United Kingdom-based charity group that assists animals. Mission Rabies has a One Health approach driven by research to eliminate dog bite transmitted rabies (a disease that is estimated to kill 59,000 people annually). Launched in September 2013 with a mission to vaccinate 50,000 dogs against rabies across India, Mission Rabies teams have since then vaccinated 1.1 million dogs and educated more than three million children in dog bite prevention in rabies endemic countries. For more information, visit www.missionrabies.com.

About Rabies Free Africa

Rabies Free Africa is empowering countries in east Africa to create self-sustaining programs to eliminate current human rabies deaths and set up surveillance systems to identify future outbreaks for containment. To reach the global goal by 2030, the focus needs to be on decreasing the cost of vaccinating dogs and increasing access to vaccines. Rabies Free Africa continues its work to discover ways to decrease the cost of mass-dog vaccinations and refine country and continent-wide programs that make the best use of limited resources. For more information, visit www.globalhealth.wsu.edu/initiatives/rabies-free-africa/.

About the Afya Program

The Afya Program comprises a number of rabies control projects supported by Merck Animal Health rabies vaccine donations, including Rabies Free Africa, Mission Rabies and The Sharon Live On Project. These projects have been brought together under the name “Afya,” which means “health” in Swahili. The Afya Program is committed to supporting the Zero by 30 Initiative, with the goal of eliminating rabies by 2030. For more information, visit www.afya.org.

About Merck Animal Health

For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook, and Twitter at @MerckAH.

i World Atlas. How Many Dogs Are There In The World? Accessed June 15, 2020. https://www.worldatlas.com/articles/how-many-dogs-are-there-in-the-world.html

ii World Atlas. How Many Dogs Are There In The World? Accessed June 15, 2020. https://www.worldatlas.com/articles/how-many-dogs-are-there-in-the-world.html

iii The World Health Organization. Frequently Asked Questions about Rabies for the General Public. Accessed June 15, 2020. https://www.who.int/rabies/Rabies_General_Public_FAQs_Sep2018.pdf?ua=1

Contacts

Merck

Media Contact:

Michael Close

+ 1 (267) 305-1211

Michael.L.Close@merck.com

, , {item content}, September 28, 2020

Categories
Business

Wedgewood Pharmacy completes acquisition of Wildlife Pharmaceuticals and its subsidiary ZooPharm; appoints new wildlife general manager

SWEDESBORO, N.J.–(BUSINESS WIRE)–#CompoundingPharmacyWedgewood Pharmacy has completed the acquisition of Wildlife Pharmaceuticals, Inc., Windsor, Colorado, and its wholly-owned pharmacy subsidiary, ZooPharm, Laramie, Wyoming. The companies serve veterinarians and patients in the wildlife and zoo markets. ZooPharm is a veterinary compounding pharmacy that provides veterinary-anesthesia and pain-management medications to care for non-domestic species, resident wildlife, captive exotic breeds, and companion animals.

The company has promoted George Carballo, currently Wedgewood Pharmacy’s regional sales manager for the Eastern U.S., to the position of general manager of Wildlife Pharmaceuticals. In his new role, Carballo will lead the Wildlife Pharmaceuticals and ZooPharm business including developing the team, coordinating resources with Wedgewood Pharmacy, increasing revenue, building and expanding customer relationships, and spurring research and new product development. He will report to Marcy Bliss, CEO of Wedgewood.

Carballo joined Wedgewood Pharmacy in October 2018 as the regional sales manager for the Eastern Region. Prior to joining Wedgewood Pharmacy, he spent 16 years at Henry Schein Animal Health as a territory manager and then regional manager. His first experience in the animal-health arena was with Fort Dodge Animal Health where he was a territory manager. He began his career in account management and sales in the health insurance industry. He holds a Bachelor of Arts degree in biology from Rutgers University.

Carballo said, “Zoos, aquariums, conservation facilities, wildlife management organizations, and private ranches need specialized medications for some of the most beautiful and endangered creatures on our planet. Wildlife animals have medication options because we have the formulation expertise to assist zoological veterinarians when these animals become ill, develop debilitating ailments, or need to be studied or managed. Through collaborative efforts, we will continue Wildlife Pharmaceuticals’ honored tradition of formulating unique compounded medications to treat a variety of species.”

Marcy A. Bliss, CEO of Wedgewood Pharmacy said: “We are honored to extend the legacy of Dr. Bill Lance and David Smith, whose career quests have been to increase the care and survival of wildlife and zoo species by developing innovative, life-saving medications. We are strongly committed to maintaining and extending the truly remarkable customer service experience and innovation that are the companies’ hallmarks.”

Among ZooPharm’s products are the BAM™ Kit, which includes a patented combination of Butorphanol tartrate, Azaperone tartrate, and Medetomidine hydrochloride that is used to immobilize a broad range of species, along with a reversal agent; a patented, slow release buprenorphine prescribed primarily to companion animals for post-operative recovery; and sustained-release analgesics and anesthetics used to manage pain. The company is licensed in 49 states.

Wedgewood Pharmacy intends to maintain the ZooPharm brand, while making Wedgewood Pharmacy’s extensive animal-health formulary available to ZooPharm’s client base. ZooPharm’s specialized products also will be offered to Wedgewood Pharmacy’s veterinary customers.

About Wedgewood Pharmacy

Wedgewood Pharmacy is the largest 503A animal-health compounding pharmacy in the U.S. and has also served the human-health market since its founding in 1980. Compounded medications are preparations customized to the unique needs of a patient. They are created and prepared by specially trained pharmacists and pharmacy technicians in state-regulated facilities when mass-manufactured drugs are not, according to the prescriber, available or are not appropriate for a patient. The company’s 503B Outsourcing Facility, Wedgewood Connect, manufactures medications under FDA’s modified cGMP standards.

In its 40 years, Wedgewood Pharmacy has grown from a local community pharmacy to become one of the largest compounding pharmacies in the United States; it is the leading pharmacy in animal health. Wedgewood Pharmacy serves more than 50,000 prescribers and hundreds of thousands of patients throughout the U.S. every year.

George (late) and Lucy Malmberg, both pharmacists, purchased Wedgewood Pharmacy in 1981; the pharmacy was founded in 1980. In June 2016, New Harbor Capital, became the majority shareholder of the company. In July 2018, the company acquired Diamondback Drugs, Scottsdale, Arizona. In 2020, the company began production at Wedgewood Connect, an FDA-registered 503B Outsourcing Facility, in San Jose, California.

Wedgewood Pharmacy is accredited by the Pharmacy Compounding Accreditation Board (PCAB®) for compliance with PCAB and other nationally recognized compounding standards. PCAB was formed by eight of the nation’s leading pharmacy associations and is a service of Accreditation Commission for Health Care. As a third-party accreditation organization, PCAB has developed the highest national standards against which providers are measured to demonstrate their ability to effectively and efficiently deliver quality compounded medications to consumers. Wedgewood Pharmacy employs more than 650 people in its state-of-the-art compounding pharmacies in Swedesboro, New Jersey and Scottsdale, Arizona, in its Wedgewood Connect 503B Outsourcing Facility in San Jose, California, and its Wildlife Pharmaceuticals/ZooPharm facilities in Colorado and Wyoming.

Contacts

Company

Marcy A. Bliss

President and CEO

MBliss@wedgewoodpharmacy.com
856-832-1303

PR Firm

David Kirk

DavidKirk@thePRguy.com
480-270-9631